Provided herein are methods of assessing or determining the presence or absence of particles, such as bead particles, present in a cell composition. Also provided are articles of manufacture and kits for use in the methods.

The invention relates to using serum exosomal proteins, α-synuclein and clusterin, as biomarkers in the prediction and identification of a subject having Parkinson's Disease, and provides methods for determining their levels. The biomarkers are also useful for monitoring, prevention and/or treatment of Parkinson's Disease and in differentiating Parkinson's disease from atypical parkinsonian syndromes including MSA.

This disclosure relates to methods for enriching a first population of cells positive for a target moiety and/or a second population of cells positive for the target moiety from a sample, wherein a level of the target moiety among the first population of cells is relatively lower than the level of the target moiety among the second population of cells. The methods of this disclosure may also be adapted to assays for determining distinct populations of cells positive for a target moiety in a sample, and to assays for optimizing enrichment conditions. Last, this disclosure relates to kits of components that may be used to carry out the methods and assays.

Provided herein are methods of assessing or determining the presence or absence of particles, such as bead particles, present in a cell composition. Also provided are articles of manufacture and kits for use in the methods.

The invention relates to isolating a selected population of exosomes with high specificity, thereby allowing accurate determination of exosomal protein content which is useful in the prediction and identification of a subject having Parkinson's Disease and in differentiating Parkinson's disease from atypical parkinsonian syndromes including MSA.

Provided herein are methods of assessing or determining the presence or absence of particles, such as bead particles, present in a cell composition. Also provided are articles of manufacture and kits for use in the methods.

The present invention relates to a method of capturing, enriching, purifying, detecting or measuring a cell in a sample at a sub-nanogram level comprising providing a nanocomposition, contacting the sample with the nanocomposition to form a mixture solution and allowing the binding of the cell with the nanocomposition, applying a magnetic field to the mixture, and evaluating the presence of or absence of the cell. The nanocomposition is capable of capturing or enriching an analyte at a sub-nanogram level, and comprise a nanostructure operably linked to an analyte-capturing member.

Disclosed are a metal nanoparticle-magnetic particle complex, comprising a core comprising a magnetic particle, the first shell comprising metal nanoparticles and formed on the surface of the core, and the second shell comprising a response factor and formed on the surface of the first shell, a method of preparing the complex, and a method of measuring the concentration of a biomarker in a sample using the complex.

The present invention relates to a method of capturing, enriching, purifying, detecting or measuring a cell in a sample at a sub-nanogram level comprising providing a nanocomposition, contacting the sample with the nanocomposition to form a mixture solution and allowing the binding of the cell with the nanocomposition, applying a magnetic field to the mixture, and evaluating the presence of or absence of the cell. The nanocomposition is capable of capturing or enriching an analyte at a sub-nanogram level, and comprise a nanostructure operably linked to an analyte-capturing member.

The present invention relates to a nanocomposition capable of capturing or enriching an analyte at a sub-nanogram level and methods thereof. The nanocomposition can comprise a nanostructure operably linked to an analyte-capturing member.